A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers

This preprint proposes a first-in-class LZK inhibitor and reports that it potentiates EGFR and PI3K pathway blockade in head and neck and esophageal squamous carcinoma. The Claidex graph holds three EGFR failures. tak-186-mvc-101-egfr-cd3-cobra-solid-tumors-phase1-2-efficacy-failure stopped a Phase 1/2 EGFR-directed T cell engager in a population that explicitly included head and neck squamous cell carcinoma, for limited anti-cancer activity. fpi-2107-egfr-cmet-nsclc-dosimetry-uptake-failure recorded a translational mismatch in which tumour uptake was limited by EGFR binding affinity. bg-60366-egfr-cdac-nsclc-strategic-shutdown closed a Phase 1 EGFR degrader on business grounds. Two of the three are efficacy or translational failures, which places this combination claim against the strongest prior-failure pattern the graph currently tracks for EGFR. The PI3K half of the proposal meets a second documented pattern, since alpelisib-epik-b3-tnbc and alpelisib-olaparib-pik3ca-ovarian-epik-o-phase3-efficacy-failure record two PIK3CA failures, one for efficacy and one for enrollment. Neither pattern bears on LZK itself, which has no failure history in the graph, so this flag applies to the proposed combination partners rather than to the novel target.